Calls for sponge test to be made widely available to prevent cancer deaths

The capsule sponge test is currently available only to higher risk patients as part of NHS trials.
The sponge on a string pill test could transform the way oesophageal cancer is diagnosed, researchers say (Cancer Research UK Cambridge Centre/PA)
PA Media
Storm Newton5 February 2024

An innovative test that involves a patient swallowing a dissolvable pill on a string should be made more widely available in order to prevent cancer deaths, a charity has said.

The capsule sponge test, previously known as cytosponge, releases a sponge to collect cells from the oesophagus as it is retrieved.

It can be used to detect abnormalities that form as part of a condition known as Barrett’s oesophagus, which makes a person more likely to develop oesophageal cancer.

Oesophageal cancer affects about 9,300 people a year, according to Cancer Research UK. It is usually diagnosed using an endoscopy, or a camera down the throat.

Symptoms can be mistaken for indigestion, such as persistent heartburn or difficulty swallowing, and often materialise in the later stages.

We have a test. We know it works. People are dying while we wait to make it widely available

Mimi McCord, Heartburn Cancer UK

The disease has a five-year survival rate of less than 20%, but this rises to 55% if detected early at stage one.

Mimi McCord, founder and chairman of the charity Heartburn Cancer UK, said: “Cancer of the oesophagus is a killer that can hide in plain sight.

People don’t always realise it, but not all heartburn is harmless. While they keep on treating the symptoms, the underlying cause might be killing them.”

Ms McCord set up Heartburn Cancer UK after losing her husband Mike, 47, to oesophageal cancer in 2002.

The group is calling for the wider adoption of the capsule sponge test in order for patients to be diagnosed earlier and given a better chance of survival.

It comes after previous studies found the test can pick up more cases of Barrett’s oesophagus compared with routine GP care.

At the moment, it is offered only to higher risk patients as an alternative to endoscopy as part of NHS pilot schemes.

It is understood they could be rolled out further if the trials yield positive results.

“We have a test. We know it works. People are dying while we wait to make it widely available,” Ms McCord said.

The capsule sponge has become one of the most exciting early detection tools to emerge in recent years

Dr Lyndsy Ambler, Cancer Research UK

Dr Lyndsy Ambler, senior strategic evidence manager at Cancer Research UK, said: “Around 59% of all oesophageal cancer cases are preventable. Yet endoscopy, the gold standard for diagnosing this cancer, is labour intensive.

“We need better tools and tests to diagnose oesophageal cancer and to identify and monitor people most at risk.

“Backed by funding from Cancer Research UK, the capsule sponge has become one of the most exciting early detection tools to emerge in recent years.

“It’s already making a difference in pilots within the NHS in England, Scotland and Wales to reduce backlogs for endoscopy from the pandemic.”

Cancer Research UK is working with the National Institute for Health and Care Research (NIHR) on the BEST4 trial, which will recruit 120,000 people in a bid to explore if the capsule sponge test can reduce deaths from oesophageal cancer.

“If this trial is successful, it could see the test rolled out more widely across the UK,” Dr Ambler said.

A spokesperson for NHS spending watchdog the National Institute for Health and Care Excellence (Nice), said: “Our guideline committee identified cytosponge as a tool which could benefit the NHS for diagnosing dysplasia and cancer, but the quality of the evidence was not sufficient to support its use at present.

“We are aware of two ongoing trials and are hopeful they could produce the evidence required to fully appraise the clinical and cost effectiveness of this potentially useful tool.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in